For example, Mishra et al. described a patient with type 2 diabetes and insulin hypersensitivity who was treated successfully with omalizumab (150 mg every four weeks; a total of 16 doses at the time of reporting), resulting in the subsequent tolerance of insulin glulisine and detemir [59]. This evidence concerns the gene INS and type 2 diabetes mellitus.